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Interleukin 26 (IL-26) is the most recently identified member of the IL-20 cytokine
subfamily, and is a novel mediator of inflammation overexpressed in activated or
transformed T cells. Novel properties have recently been assigned to IL-26, owing to
its non-conventional cationic, and amphipathic features. IL-26 binds to DNA released
from damaged cells and, as a carrier molecule for extracellular DNA, links DNA to
inflammation. This observation suggests that IL-26 may act both as a driver and an
effector of inflammation, leading to the establishment of a deleterious amplification
loop and, ultimately, sustained inflammation. Thus, IL-26 emerges as an important
mediator in local immunity/inflammation. The dysregulated expression and extracellular
DNA carrier capacity of IL-26 may have profound consequences for the chronicity of
inflammation. IL-26 also exhibits direct antimicrobial properties. This review summarizes
recent advances on the biology of IL-26 and discusses its roles as a novel kinocidin.
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Cytokines are a class of signaling molecules expressed by many cell types, and especially those
of the immune system. They are classified in seven major families: the type I cytokine, the type
II cytokine (1), the IL-1 (2), and the TGF-β (3) families, the TNF superfamily (4), the receptor
tyrosine kinase cytokine family (5), and the chemokine family (6). Although exhibiting pleiotropic
properties, they are pivotal regulators of innate and adaptive immune defenses, inflammation,
and hematopoiesis.
The term “interleukin” (IL) originally refers to a group of cytokines expressed by leukocytes.
To date, interleukins have been reported expressed by a wide variety of immune and non-immune
cells and exhibit a large panel of properties (e.g., affecting proliferation, activation, differentiation,
maturation, migration, and adhesion). Although agonist/antagonist activities and redundancy
make any classification particularly complicated, different classifications have been proposed
based on their functions, receptor usage or structure. As an example, a functional classification
distinguishes eight subgroups of interleukins (IL-1, common γ chain receptor cytokine, cytokines of
type 2 immune responses, interleukins with chemokine activity, the IL-10, IL-12, and IL-17 families
and, others) (7). A structure-based classification has been also proposed, dividing interleukins into
four major groups: IL-1-like cytokines, class I helical cytokines (IL-4-, IL-6-, and IL-12-like ILs,
common γ chain receptor cytokines), class II helical cytokines (IL-10- and IL-28-like molecules)
and the IL17-like cytokines (8).
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The interleukin 10 (IL-10) cytokine family consists of
nine members: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, and
the more distantly related IL-28A, IL-28B, and IL-29 (also
named type III interferons) (9). Except IL-10 which exhibits
immunoregulatory properties, most members of the IL-10
cytokine family are involved in mucosal immunity (i.e., local
immunity, maintenance/restoration of tissue homeostasis, tissue
repair), such as IL-22 involved in gut homeostasis, and local
immunity (10).
Interleukin 26 (IL-26) is one the most recently identified
member of the IL-10 cytokine family (11). Initial studies
reported an elevated expression in human chronic inflammatory
diseases, leading to a proposal that it may constitute
a novel inflammatory mediator (12, 13). Although the
absence of IL-26 in rat and mouse has strongly hampered
our understanding of its biology, recent reports have
shed new light on the functions of IL-26, revealing that
it exhibits conventional, and non-conventional cytokine
properties. This review summarizes recent data on the
biology of IL-26 and its potential pathological roles in
inflammatory disorders.
THE IL-26 PROTEIN AND SIGNALING
ELEMENTS
Gene Organization
Firstly named AK155, IL-26 was identified as a transcript
over-expressed in Herpesvirus saimiri (HVS)-infected
human T-cells (11). Due to sequence (≈25% homology
and 47% similarity) and predicted secondary structure
similarities with IL-10, AK155 was categorized in the IL-10
cytokine family, a subgroup of the class II helical cytokine
family (14).
The organization of the IL26 gene has been previously
detailed (12). Briefly, it is located on chromosome 12 (12q15)
(15, 16), between the genes encoding IL-22 and interferon
gamma (IFNγ), and contains five exons. IL26 and IFNG genes
have the same orientation and share a common enhancer
sequence located between the two genes. The IL26 gene is
conserved in various vertebrates (ranging from fish to great
apes) and human IL-26 orthologs have been identified in
137 organisms, with the notable exception of mouse and
rat (17).
Abbreviations: AAV, ANCA-associated vasculitis; Ab, antibody; ACD, allergy
contact dermatitis; AMP, antimicrobial peptide; ANCA, anti-neutrophil
cytoplasmic antibodies; CMV, cytomegalovirus; CPP, cell-penetrating peptide;
CRF, cytokine receptor family; CTCL, cutaneous T cell lymphoma; DC, dendritic
cells; GVHD, graft-vs. -host disease; HSV-1, herpes simplex virus 1; HVS,
herpesvirus saimiri; IBD, inflammatory bowel disease; IFN, interferon; IL,
interleukin; ILC, innate lymphoid cell; IPM, in-plane membrane; Jak, janus
kinase; MS, multiple sclerosis; NK, natural killer; pDC, plasmacytoid dendritic
cells; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor
kappa-B ligand; SMC, smooth muscle cell; STAT, signal transducer and activator
of transcription; STING, stimulator of interferon genes; TLR, toll-like receptor;
TNF, tumor necrosis factor; Treg, regulatory T lymphocytes; Tyk, tyrosine kinase;
VSV, vesicular stomatitis virus.
FIGURE 1 | 3-D structural models of IL-26. (A) A three dimensional structure
of IL-26 has been modeled using the IL-10 crystal structure as a template. The
six alpha-helices are colored. (B) Electrostatic potential on the molecular
surface of IL-26 is colored from red (+210 kbT/ec) to blue (+10 kbT/ec). The
alpha-helices are shown.
Protein Characteristics
IL-26 exhibits characteristics of cytokines, i.e., six alpha helices
(A–F) connected by loops and four conserved cysteines
(Figure 1A). The protein comprises 171-amino acids, with a
calculated molecular mass of 19,843 Da. Western blotting
revealed that recombinant IL-26 has an apparent molecular mass
of 19 kDa and that endogenous IL-26 (present in T cell culture
supernatants and in human serum) is expressed as a 36 kDa
homodimer (11). Meller et al. also predicted a multimeric form
of IL-26 (18), but this remains to be confirmed in vivo.
IL-26 contains 30 positively charged amino acids (lysine
or arginine), conferring to IL-26 unusual physicochemical
properties, including a high isoelectric point of 10.77 (11).
3-D modeling reveals the distribution of positively charged
residues on the surface of the molecule, providing to IL-26
particular features: the electrostatic potential on the molecular
surface is globally positive (11, 19) and, more importantly,
the helices E, and F exhibit amphipathic properties (18, 19),
with a hydrophic face and a hydrophilic face comprised of
positively charged residues (Figure 1B). Consequently, helices E
and F, and part of helix C, are enriched in positively charged
residues, conferring to IL-26 DNA-binding properties (18, 19).
Interestingly, amphipathic α helices containing DNA-binding
domains are hallmarks of cationic cell-penetrating peptides
(CPP), a family of molecules shuttling extracellular molecules,
and especially nucleic acid, into intracellular compartment (20,
21). In agreement, helix F has similarities with the KALA
peptide, a synthetic CPP designed for intracellular DNA delivery
(20). Consequences of these physicochemical features were only
recently understood (18, 19).
IL-26-Signaling Elements
The Conventional IL-26 Receptor
Biological activities of the IL-10 family cytokines are mediated by
specific membrane receptors belonging to the cytokine receptor
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family 2 (CRF2) and comprised of heterodimeric combinations
of receptors 1 (IL-10R1, IL-20R1, or IL-22R1) and receptors 2
(IL-10R2 or IL-20R2) (22).
Two independent laboratories identified a conventional
receptor for IL-26 (IL-26R), consisting in IL-10R2 and IL-20R1
chains (23, 24). The IL-26-binding site is located within the IL-
20R1 subunit and both chains are required for signaling (12).
IL-26 triggers Janus kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2)
signaling, resulting in the phosphorylation of signal transducer
and activator of transcription 1 (STAT1) and STAT3 (23, 24).
Interestingly, although IL-10R2 is ubiquitously expressed, IL-
20R1 is restricted to epithelial cells (22); IL-20R1 has been also
reported expressed by some myeloid cells (25, 26).
Other IL-26-Signaling Molecules
Different studies have reported that IL-26 activates innate (27)
and adaptive lymphoid cells (28) as well as myeloid cells (29)
and plasmacytoid dendritic cells (pDC) (18). However, with
the exception of alveolar macrophages (25) and non-stimulated
neutrophils (26, 30), immune cells do not express IL-20R1,
suggesting the existence of alternative IL-26-signaling pathway(s)
in the activation of IL-20R1-negative cells.
A major breakthrough in the biology of IL-26 came from
the demonstration that it acts as a shuttling molecule allowing
DNA to be internalized by pDC, leading to their activation via
the intracellular DNA sensor toll-like receptor 9 (TLR9) (18).
We confirmed this unique property by showing that IL-26/DNA
complexes activate human monocytes via the inflammasome
and the cytosolic stimulator of interferon genes (STING)
pathways (19).
Different hypotheses have been proposed to explain how IL-
26 may enter into the cytoplasm in the absence of a conventional
membrane receptor and there activate innate immune cells. First,
IL-26 can bind to glycosaminoglycans (heparin and heparan
sulfate) on the plasma membrane (11, 18, 31). Second, helix
F was predicted to have an in-plane membrane (IPM) motif
anchor (19), a domain involved in the binding of proteins to cell
membranes and their subsequent internalization (32). Third, IL-
26 exhibits features of cell-penetrating peptides (CPP) that have
the ability to translocate through membranes in a non-specific
manner (33).
The existence of different signaling pathways is suggested
by the fact that monomeric and dimeric IL-26 differ in their
abilities to stimulate IL-26R-expressing epithelial cells vs. IL-
20R1-deficient immune cells (29). Nevertheless, whether IL-26
may activate cells via the conventional IL-26R and intracellular
nucleic acids sensors remains undetermined, especially as these
pathways induce similar activation profiles.
Expression of IL-26
The production of IL-26 by activated primary and transformed
T cells and by inflammatory immune and non-immune cells
is well-established. However, as reported in recent reviews (13,
34), further sources of IL-26 as well as further IL-26-dependent
signaling pathways and phenotypes are to be expected due to the
non-conventional properties exhibited by IL-26 (accumulation
within cells as a result of its CPP and carrier properties).
Expression by Innate and Adaptive Lymphoid Cells
Since the initial discovery of IL-26 expression in human HVS-
transformed T cells (11), several studies have confirmed that
lymphoid cells, and especially activated T helper 1 (Th1) and
Th17 memory CD4+ cells, constitute the major source of
IL-26. More precisely, IL-26 is expressed by infiltrating pro-
inflammatory IL-17-producing T cells present in chronically
inflamed tissues from patients suffering from intestinal bowel
diseases (IBD) (35) or from joint (29), skin (36, 37), liver (27),
or lung inflammation (25, 38, 39). Activated memory CD146+
CD45RO+ CD4+ T cells strongly express IL-26mRNA compared
to CD146+ CD45RO− CD4+ T cells (40). Moreover, Ohnuma
et al. have reported that CD26+ CD4+ T cells are a major source
of IL-26 in a model of graft-vs.-host disease (GVHD) (39). IL-
26 has also been reported expressed by CD8+ T cells (25, 41). In
contrast, CD4+ T cells polarized toward a regulatory phenotype
(Treg) and Th2 lymphocytes have low or no expression of IL-26
(42). Finally, naive CD4+ T cells also express IL-26, but at a lower
level compared to memory CD4+ T cells (42). Thus, IL-26 has
emerged as a marker of highly differentiated Th17 cells (36).
The nature of the signals required for IL-26 expression by
human T cells remains largely unknown. IL-1β and IL-23, two
cytokines crucial for the generation of human Th17 cells (43),
induce IL-26 production by CD4+ T lymphocytes (44, 45) and,
conversely, IL-26-stimulated CD4+ T cells secrete IL-17, and
IL-23 (46). This loop of cytokine induction may participate
in the maintenance of the pro-inflammatory phenotype of
infiltrating memory T cells within IL-26-containing inflamed
tissues. Interestingly, the expression of IL-26 by CD4+ T cells
can be induced via signaling pathways other than CD3 and CD28
[(42) and personal unpublished data]. Accordingly, cord blood
human CD4+ T cells acquire IL-26 expression upon interacting
with CD26 with its ligand caveolin-1 (39, 47). However, and
contrary to activated memory CD4+ T cells, CD26-induced IL-
26+ CD4+ T cells do not express IL-2, IFNγ, and IL-17A. To date,
a role for CD26 in the expression of IL-26 by effector memory T
cells has not been reported.
IL-22-expressing natural killer (NK) cells, also called NK22
or innate lymphoid cell 3 (ILC3), are a NK cell subset present
in mucosa-associated lymphoid tissues and involved in immune
surveillance at mucosal surfaces (48). Mature NK22 cells, as well
as stage 3 human immature CD34− CD117+ CD161+ CD94−
CD56− NKp44− NK cells, which may constitute precursors of
mature NK22 cells (49), constitutively express IL-26 mRNA (50–
52). In line with this observation, IL-22-expressing, and IL-26-
producing CD4+ T cells have been detected within skin chronic
wounds due to Staphylococcus aureus (53).
Expression by Monocytes/Macrophages
Contradictory results are reported in the literature concerning
the expression of IL-26 by monocytes. Although Wolk et al.
showed that IL-26 is not expressed by monocytes (42, 54),
other authors reported that monocytes constitutively express
IL-26 mRNA, although at a low level compared to memory
T lymphocytes (55). Similar contrasting results are reported
on its expression by activated monocytes. IL-26 mRNA
expression appears down-regulated in monocytes infected by
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Mycobacterium tuberculosis (55) while, in contrast, a stimulation
with LPS plus IFNγ, in the presence of a neutralizing anti-IL-
10 Ab, induces its secretion (56). Furthermore, lung alveolar
macrophages from healthy volunteers secrete IL-26 after local
exposure to endotoxin (25).
Expression by Non-immune Cells
Whereas IL-26 emerges as a mediator potentially involved in the
control of tissue homeostasis, only a few studies have reported its
expression by epithelial cells. Nevertheless, it has been shown that
the synthetic TLR3 agonist poly[I:C] acts synergistically with IL-
17A to induce IL-26 expression in primary bronchial epithelial
cells (57). The expression of IL-26 was confirmed in bronchial
brush biopsies from healthy subjects (57).
IL-26 has been also detected in the joints of patients suffering
from rheumatoid arthritis (RA) (29) and spondyloarthritis (58).
More precisely, IL-26 is expressed by fibroblast-like synoviocytes
and, to a lower extent, by CD68+ macrophage-like synoviocytes
present in inflamed joints from RA patients. The expression
of IL-26 by fibroblast-like synoviocytes is potentiated by the
inflammatory cytokines IL-1β and IL-17A (29). A recent study
confirms the expression of IL-26 by α smooth muscle actin-
expressing myofibroblasts in spondyloarthritis patients (58). We
also reported the in vitro expression of IL-26 by primary smooth
muscular cells (SMC), which is enhanced upon stimulation with
IL-1β and TNFα (19). IL-26 is also detected in renal arterial
SMC in patients with anti-neutrophil cytoplasmic antibodies
(ANCA)-associated vasculitis (AAV) (19).
BIOLOGICAL PROPERTIES OF IL-26
Due to its absence in mice and rat, most of the biological
properties of IL-26 have been described ex vivo using human cells
(12, 13), mainly in inflammatory backgrounds (27, 29, 35, 59).
Recent important studies have demonstrated that IL-26 is not
strictly a cytokine but can also act as a carrier for extracellular
DNA (18, 19) and as an antimicrobial molecule (18), thanks to
its particular biochemical properties. These properties (Figure 2)
suggest that IL-26 can be categorized as a kinocidin, an emerging
family of proteins involved in intercellular dialog and sharing
bactericidal properties (60–62).
Effects on Non-immune Cells
Based on the original observation of an elevated expression of
IL-26 in Crohn’s disease (35), the authors reported that IL-26
induces the expression of the pro-inflammatory cytokines IL-8
and TNFα as well as the regulatory cytokine IL-10 in human
gut epithelial cells (35). This activation of epithelial cells is
mediated via the conventional IL-26R and involves STAT1 and/or
STAT3 (24, 35). The capacity of IL-26 to stimulate epithelial
cells was confirmed in a study reporting that IL-26 induces the
secretion of inflammatory cytokines by the keratinocyte cell line
HaCat and, to a lower extent, by human primary keratinocytes
(24). In contrast to other members of the IL-10 cytokine
family, IL-26 does not induce the proliferation of primary
human keratinocytes, but does induce STAT3 phosphorylation
in these IL-26R-expressing cells (26); however, the expression of
inflammatory molecules was not monitored in this study.
In response to soluble mediators secreted by IL-26-expressing
ILC3 cells, epithelial cells produce IL-10, and express a variety of
mitogenic and anti-apoptotic molecules (50); however, the role of
IL-26 in this process remains to be elucidated.
It is important to note that most of the above results were
obtained using transformed cell lines and that a variety of
other cell types, originating from pancreas, colon, cervix, skin,
bone marrow or liver, do not respond to IL-26 (24). Moreover,
contrasting results have also been reported using primary
epithelial cells. As an example, IL-26 inhibits the production of
IL-1β, TNFα, IL-8, and GM-CSF by primary bronchial epithelial
cells (25) and a recent study reports that IL-26, as well as the
inflammatory cytokines IL-17 and IL-22, affect the paracellular
permeability in an in vitromodel of respiratory epithelial barrier
using primary human nasal epithelial cells (63). Similarly, IL-
26 inhibits the proliferation of intestinal epithelial cells (35),
while, in contrast, it promotes the growth of gastric tumor
cells (64).
Effects on Immune Cells
Several studies have reported that IL-26 induces the
production of pro-inflammatory cytokines by innate
immune cells.
Myeloid Cells
IL-26 induces the production of the pro-inflammatory cytokines
IL-1β, IL-6, and TNFα by human monocytes (29). In agreement
with the fact that IL-1β is pivotal in the generation of
human Th17 cells (65), IL-26-treated monocytes induce the
differentiation of non-committed memory CD4+ T cells into
Th17 lymphocytes (29). Interestingly, IL-26-induced Th17 cells
express IL-26, allowing initiating of an amplification loop
between Th17 cell polarization, and inflammatory cytokine
secretion that could participate in the maintenance of a pool
of activated Th17 cells. IL-26 also induces human monocytes
to express numerous chemokines involved in the recruitment
of innate and adaptive immune cells (29). Che et al. confirmed
these results by showing that IL-26 induces the release of the
neutrophil-mobilizing cytokines IL-1β, TNFα, and GM-CSF by
primary immune cells isolated from endotoxin-primed human
airways (25).
Monocytes are precursors of macrophages, dendritic cells,
and osteoblasts, highly specialized tissue-resident cells whose
generation is driven by local signals. Osteoblasts and osteoclasts,
which are involved in bone remodeling, are responsive to
IL-26. IL-26 inhibits the bone-resorbing activity of mature
osteoclasts (66) and increases bone mineralization by human
osteoblasts (58).
IL-26 also primes neutrophils to IL-8- and fMLP-induced
chemotaxis (but not chemokinesis) and to anti-bacterial activity
(25). The capacity of neutrophils to respond to IL-26 has
been confirmed in vivo. Indeed, an intranasal instillation of
recombinant human IL-26 facilitates the recruitment of innate
immune cells toward the bronchoalveolar space after a local
stimulation with LPS (25, 57).
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FIGURE 2 | Biological properties of IL-26. The binding of IL-26 to the conventional receptor composed of the IL-20R1 and IL-10R2 chains induces the production of
inflammatory cytokines. IL-26 can also act as a carrier molecule allowing extracellular DNA to get access to intracellular nucleic sensors. Both pathways induce the
production of inflammatory cytokines, chemokines, and type I and type II interferons by selected immune and non-immune cells. IL-26 also acts as an antimicrobial
protein (AMP) through its capacity to form pores in bacterial membranes.
Lymphoid Cells
IL-26 triggers NK cell activation, as evidenced by their induced
expression of the inflammatory cytokines IL-1β and TNFα.
Importantly, IL-26 also promotes the production of type I (IFNβ)
and type II (IFNγ) interferons (27), that induce and orchestrate
innate and adaptive antiviral responses. Consistent with this
observation, IL-26-treated human NK cells express elevated
levels of membrane-anchored TRAIL, allowing them to kill
hepatitis C virus (HCV)-infected hepatocytes (27). Whether the
activation of IL-26R-negative NK cells by IL-26 is also dependent
on its capacity to shuttle extracellular DNAwithin lymphoid cells
remains to be determined.
The capacity of IL-26 to act on adaptive immune cells remains
to be clarified. Hummelshoj et al. have reported that IL-26
inhibits the production of IgA and IgG by B lymphocytes
activated by an anti-CD40 Ab and the production of IgG4
induced by anti-CD40 Ab plus IL-4 (28). To date, no direct effect
of IL-26 on naive and memory human T cells has been reported.
Other Immune Cells
Plasmacytoid DC have a central role in the antiviral arsenal,
thanks to their capacity to produce important amounts of IFNα
(67). When combined with DNA, IL-26 induces the production
of IFNα by human pDC (18).
Antimicrobial Properties
IL-26 exhibits a direct antimicrobial activity, a property related
to its biochemical, and structural similarities with antimicrobial
peptides (AMP) (18, 19).
Antiviral Activity
Braum et al. reported for the first time a biological activity of IL-
26 which is not dependent on cell activation, by showing that IL-
26 modulates the rate of cell infection by enveloped viruses (31).
More precisely, a pre-incubation of vesicular stomatitis virus
(VSV) with IL-26 increases the rate of infection of the epithelial
cell line Colo-205, whereas an opposite effect is observed with
the human Cytomegalovirus (CMV). In contrast, IL-26 does not
modulate the infection of the epithelial cell line Vero by Herpes
virus simplex 1 (HSV-1). Interestingly, the capacity of IL-26 to
modulate viral infectivity appears independent of the expression
of IL-26R (31). Even though the mechanism involved has not
been elucidated, the authors suggested that the biochemical
properties of IL-26 may be responsible, at least in part, for the
protective activity of IL-26. This hypothesis is supported by
previous studies showing that AMP can prevent virus infectivity
by (i) causing virus membrane instability, rendering them unable
to infect host cells (68, 69), or (ii) by interfering with the virus
binding to host cells (through interaction with binding structures
of the virus or with receptors at the surface of target cells) (70–
72). A role for IL-26 in antiviral defense is also supported by its
overexpression in the embryonic zebra fish cell line ZF4 infected
by the aquatic Birnavirus Infectious pancreatic necrosis virus (73).
AMP can also kill some enveloped viruses (74, 75). Whether
IL-26 may also kill enveloped virus, in a way similar to AMP,
remains unknown.
Antibacterial Activity
In 2015, the group of M. Gilliet reported that IL-26 acts as
an antibacterial molecule (18). The initial hypothesis for the
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mechanism of this action was based on the particular distribution
of charges at the surface of IL-26, similar to AMP. IL-26 kills or
inhibits the growth of a variety of Gram positive (Staphyloccocus
aureus) and Gram negative bacteria (Pseudomonas aeruginosa,
Escherichia coli, Klebsiella pneumoniae) at concentrations similar
to the antimicrobial molecule LL-37. The antimicrobial activity of
IL-26 relies on its capacity to form pores and to disrupt bacterial
membranes, as indicated by the presence of membrane blebs
on the surface of the bacteria and cytosolic leakage pores in
bacterial walls.
The antibacterial activity of IL-26 was also suspected to
rely on its capacity to organize into multimers, thanks to
the absence of a conserved proline residue (P113) which is
involved in the formation of arm-exchange dimers in the
other members of the IL-10 cytokine family. The authors also
identified lipopolysaccharide and lipoteichoic acid as IL-26-
binding elements at the surface of bacteria (18). Interestingly,
the biological activity of IL-26 present in T cell culture
supernatants was superior to that of recombinant proteins
produced in prokaryotes (18). Post-translational modifications
and/or multimer organization have been proposed to account for
the superior activity of natural IL-26 compared to recombinant
IL-26. Interestingly, the authors confirmed the antimicrobial
activity of IL-26 in an in vivomodel of sepsis (18).
The antimicrobial activity of IL-26 was recently confirmed
by Woetmann et al. who showed that it triggers Staphylococcus
aureus death and inhibits biofilm formation (53). In contrast,
IL-26 does not affect the growth of Propionibacterium acnes (76).
IL-26 has also an indirect antimicrobial activity via inducing
the production of type I and type II interferons by pDC,
monocytes, and NK cells (18, 19, 27). Interestingly, IL-26 seems
to be necessary for pDC activation, as killed Pseudomonas
aeruginosa alone is unable to induce IFNα production (18).
These biological activities allow categorization of IL-26 as a
membrane-active AMP (77, 78).
INTERLEUKIN-26 IN HUMAN DISEASES
Deciphering the biology of IL-26 was hampered by the absence
of the IL26 gene in mice and rat. As initial studies revealed that
activated memory Th17 cells are the main producers of IL-26
(35, 45), its properties were mostly examined in the context of
chronic inflammatory and infectious diseases.
Collectively, these studies identified IL-26 as a master
regulator of inflammation. Even though IL-26 can signal via
the heteroduplex IL-20R1–IL-10R2 (12, 13), accumulating data
suggests that the proinflammatory activity of IL-26 may rely on
its capacity to form complexes with extracellular DNA (18, 19)
in a context of chronic and severe inflammation associated with
cell death and tissue destruction. Indeed, extracellular nucleic
acids, released by damaged cells, have emerged in the recent
past as major inflammation driving signals (79). It is important
to note that extracellular DNA has to complex with shuttling
molecules to get access to intracellular DNA sensors, underlining
the role of carrier molecules in rendering extracellular DNA
pro-inflammatory.
FIGURE 3 | Schematic representation of the proinflammatory properties of
IL-26. IL-26, produced by activated memory Th17 cells and NK22 cells,
induces the production of inflammatory mediators by epithelial cells and favors
the generation of inflammatory Th17 cells (induction of IL-1β and IL-23 by
monocytes). In case of chronic inflammation, IL-26 can bind to extracellular
DNA released by dying cells into the extracellular milieu (at sites of extensive
tissue damaged). The IL-26-DNA complexes can then activate innate immune
cells (such as monocytes), initiating a deleterious amplification loop leading to
chronic inflammation, and tissue damages.
Importantly, recent studies also suggest that IL-26 may act as
a dangerous catalyst that could contribute to the establishment
of chronic inflammation. Indeed, the production of IL-26 is
induced by inflammatory cytokines which, conversely, induces
the production of inflammatory mediators. This mechanismmay
establish a deleterious positive feedback loop (i.e., production
of IL-26 by activated Th17 cells and release of DNA by dying
cells as a result of chronic tissue damage) leading to unabated
inflammation after elimination of the initiating signal (Figure 3).
The biological properties of IL-26 and related roles in human
diseases are summarized in Table 1.
Chronic Viral Infection
The levels of circulating IL-26 are increased in HCV-infected
patients and are correlated with the inflammation stage of
the liver (27). IL-26 is expressed by circulating CD4+ T
cells and infiltrating liver T cells. It also accumulates in
hepatocytes from chronically infected HCV-infected patients,
although the mechanism involved remains undetermined as
infected hepatocytes do not express IL-26 mRNA. Inflammation
is part of the antiviral immune response; the pro-inflammatory
and NK cell-stimulatory activities of IL-26 may also contribute to
the control and/or elimination of virus-infected cells (27).
Inflammatory Disorders
Several genetic studies have suggested a potential role for
IL-26 in the pathophysiology of chronic inflammatory and
autoimmune disorders. IL26 gene polymorphisms are associated
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TABLE 1 | Biological properties of IL-26 and related human diseases.
Target Impact Mechanism of action Related human diseases References










Collagen synthesis IL-10R2 – IL-20R1 GVHD
(bronchiolitis obliterans)
(39)
Myeloid cells Production of inflammatory
cytokines and of type I IFN





(18, 19, 29, 58, 84)
Lymphoid cells Production of IFNγ
Enhanced NK cell cytotoxicity
Unknown Chronic HCV infection (27)
Plasmacytoid cells Production of inflammatory
cytokines and of type I IFN





Virus Modulation of viral replication
(inhibition or activation)





Formation of pores Sepsis
IBD
(18, 85)
IBD, inflammatory bowel disease; GVHD, graft-vs.-host disease; HCV, hepatitis C virus; RA, rheumatoid arthritis.
with an increased risk for developing multiple sclerosis (MS)
(86) or RA (15). Moreover, elevated levels of circulating and
tissue-associated IL-26 are reported in Th17 cell-mediated
autoimmune diseases, such as Crohn’s disease, RA, psoriasis,
and AAV.
Inflammatory Bowel Diseases
The role of IL-26 in IBD was first suggested by a genetic
association study which identified rs2870946 polymorphism as a
strong predictive factor (80).
The levels of circulating IL-26 are elevated in patients with
Crohn’s disease and an increased expression of IL-26 mRNA is
observed within inflammatory colonic lesions (24, 35, 81). The
expression of the transcript encoding IL-26 is also increased
in the colonic lesions of pediatric-onset ulcerative colitis (82).
The expression of Th17 pathway-associated genes, including IL-
26, is enhanced in inflamed colonic samples from IBD patients
compared to controls, and their levels are correlated with disease
severity (83). More specifically, in Crohn’s disease, RORγt+ Th17
cells infiltrating inflamed mucosa secrete IL-26 which can, in
turn, induce the secretion of inflammatory cytokines by epithelial
cells (35).
In patients with common variable immune deficiency
associated with inflammatory complications, IL-22+ IL-
26+ NK22 cells are expanded in the blood and infiltrate
gastrointestinal, and lung tissues (51). Pinero et al. reported
that peripheral blood mononuclear cells from Crohn’s disease
patients with a variant IL26 genotype (varIL26) have a reduced
capacity to kill bacteria compared to wild type IL26-genotyped
(wtIL26) patients and that the varIL26 genotype is associated
with reduced IL-26 serum levels (87). Although Crohn’s disease
patients with wtIL26 or varIL26 genotypes exhibit similar rates
of circulating bacterial DNA, the concentrations of IFNγ, IL-12,
and TNFα are elevated in patients with a varIL26 genotype
and containing circulating bacteria DNA. The authors suggest
that IL26 polymorphisms may impact bacterial DNA clearance
and, consequently, the amplitude and duration of inflammatory
responses in IBD patients (87).
Rheumatoid Arthritis
The levels of IL-26 are increased in the sera and synovial fluids
of RA patients, compared to healthy subjects. Moreover, in
RA patients, the levels of IL-26 are higher in synovial fluids
than in the serum, suggesting a local production in inflamed
joints (29).
The role of IL-26 in inflammatory articular diseases has been
recently confirmed in a study showing that the levels of IL-
26 are increased in the synovial fluids of patients suffering
from spondyloarthritis (58). However, IL-26 does not appear
directly involved in the bone destruction process, as it suppresses
RANKL-induced osteoclastogenesis (66).
Vasculitis
ANCA-associated vasculitis is a chronic relapsing autoimmune
inflammatory disease associated with extensive cell death. Acute
flares are characterized by necrotic lesions in microvessels
where the massive accumulation of dying neutrophils
induces the subsequent recruitment and activation of
immune cells, especially in granulomatous lesions (88, 89).
The inflammatory process is suspected to result from
the release of neutrophil self DNA into the extracellular
milieu (90).
Patients with active AAV have high levels of both circulating
IL-26 and IL-26-DNA complexes, especially during acute
flares (19). Moreover, in patients with rapidly progressive
glomerulonephritis, IL-26 deposits in necrotizing lesions
(19). These data support our hypothesis that IL-26-DNA
complexes expressed in inflammatory lesions may initiate a
positive amplification loop between extensive cell death and
chronic inflammation.
Increased levels of IL-26 are also detected in the sera of
patients suffering from Behçet’s disease, a rare auto-inflammatory
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disorder with manifestations of vasculitis; in this context, IL-
26 levels correlate with disease severity and it accumulates in
inflammatory lesions (46, 91).
Other Chronic Inflammatory Diseases
An accumulation of IL-26 has been reported in psoriasis lesions
(18, 45). IL-26 mRNA and protein were also evidenced in early
primary systemic sclerosis skin lesions and its expression was
positively correlated with the disease activity score (37). However,
the role of IL-26 in the pathophysiology of this disease remains to
be investigated.
Although the levels of IL-26 were reported elevated in MS
patients treated with IFNβ (92), a recent study did not find any
statistically significant modulation of IL-26 mRNA expression
between healthy controls and stable or relapsingMS patients (93).
Graft vs. Host Disease
Chronic inflammation can lead to fibrosis (94). However,
the potential role of IL-26 in this process has been only
evoked in a study using a mouse model of pulmonary
chronic GVHD (95). The authors showed that sub-lethally
irradiated NOD/Shi-scidIL2rgnull mice transplanted with human
umbilical cord blood develop symptoms of chronic GVHD,
such as bronchiolitis obliterans, scleroderma, and primary biliary
cirrhosis-like lesions. IL-26 increases collagen synthesis by
fibroblasts, promoting lung fibrosis during GVHD induced after
the adoptive transfer of IL-26+ CD4+ T cells to IL-26-transgenic
mice. The key role of IL-26 was reinforced by the demonstration
that a neutralizing anti-IL-26 Ab decreased collagen deposition
in pulmonary chronic GVHD in mice.
In humans, immunohistochemistry detected an infiltration of
IL-26+ CD26+ CD4+ T cells within bronchial fibrotic lesions in
a patient suffering from bronchiolitis obliterans after allogenic
hematopoietic stem cell transplantation (39, 47).
Allergy
A single nucleotide polymorphism (rs3741809) in the IL26 gene
is associated with susceptibility to allergic rhinitis (96) and the
levels of IL-26 in sputum samples are positively correlated with
pediatric asthma severity (17). More recently, the role of IL-26
in allergic contact dermatitis (ACD) has been investigated. In
this disease, skin injuries have been assumed to be related to T
cell-mediated cytotoxicity against keratinocytes. The expression
of IL-26 is increased in the sera and in the skin of ACD
patients (elevated IL-26 mRNA expression and infiltration of
IL-26-expressing cells in skin lesions), compared to healthy
subjects. In vitro, peripheral blood mononuclear cells (PBMC)
isolated from ACD patients have a higher cytotoxic activity
against the keratinocyte cell line HaCat compared to PBMC from
healthy subjects. Interestingly, the cytotoxic activity was strongly
decreased after silencing IL-26 mRNA expression (84).
Cancer
IL-26 mRNA is highly expressed in cutaneous biopsies of
patients with primary cutaneous T-cell lymphomas (CTCL),
at levels similar to patients with psoriasis (97). Many cancers
may arise from sites of infection and/or chronic irritation and
inflammation. Moreover, inflammation modulates neoplastic
processes, proliferation, and migration of tumor cells. As IL-26
is a pro-inflammatory cytokine, one can suspect that it may also
participate in tumor initiation and/or progression. Studies are
needed to clarify this important question.
CONCLUSION
IL-26 has emerged as an inflammatory mediator acting upstream
in the inflammation cascade. Nevertheless, and contrary to other
members of the IL-10 family cytokines, the pro-inflammatory
properties of IL-26 appear mainly related to its ability to act as
a carrier of extracellular DNA, a property that would be most
important during chronic inflammation which is associated with
tissue damage. This unique property identifies IL-26 as a master
driver of chronic inflammation.
IL-26 also exhibits antibacterial properties, thanks to its
particular structural similarities to AMP.
Importantly, most of the biological functions of IL-26 have
been identified in pathological situations that feature chronic
inflammation. Thus, the roles of IL-26 in normal physiology
remain largely unknown. One can hypothesize that IL-26 could
be involved in mucosal innate immunity, as suggested by
its expression in colon, ileum, Payer’s patches, and tonsils.
Deciphering its physiological properties is of importance, notably
since neutralizing IL-26 has been proposed as a novel therapeutic
strategy for some Th17-associated disorders.
In light of recent studies, it becomes evident that IL-26 is
more than a cytokine. The dual ability to act as a cytokine and
as an AMP allows classification of IL-26 in the kinocidin family.
Nevertheless, our knowledge of the biology of IL-26 remains
fragmentary and future studies are required to decipher the
biology of this amazing molecule.
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